Tang Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,573,530
| Closed | -$92.1M | – | 51 |
|
|
2026
Q1 | $92.1M | Hold |
4,573,530
| – | – | 4.68% | 10 |
|
|
2025
Q4 | $73.9M | Sell |
4,573,530
-468,268
| -9% | -$6.2M | 3.65% | 10 |
|
|
2025
Q3 | $61.4M | Buy |
5,041,798
+100,000
| +2% | +$1.38M | 2.36% | 8 |
|
|
2025
Q2 | $55.9M | Hold |
4,941,798
| – | – | 2.82% | 7 |
|
|
2025
Q1 | $57M | Buy |
4,941,798
+47,951
| +1% | +$489K | 3.16% | 6 |
|
|
2024
Q4 | $41.5M | Buy |
4,893,847
+572,300
| +13% | +$5.93M | 2.74% | 8 |
|
|
2024
Q3 | $50M | Buy |
4,321,547
+102,718
| +2% | +$1.29M | 3.57% | 6 |
|
|
2024
Q2 | $49.7M | Buy |
4,218,829
+93,484
| +2% | +$1.09M | 5.06% | 3 |
|
|
2024
Q1 | $48.9M | Buy |
4,125,345
+685,000
| +20% | +$9.13M | 5.09% | 3 |
|
|
2023
Q4 | $42.1M | Hold |
3,440,345
| – | – | 3.89% | 4 |
|
|
2023
Q3 | $33.1M | Buy |
3,440,345
+788,952
| +30% | +$8.06M | 4.67% | 4 |
|
|
2023
Q2 | $23.9M | Hold |
2,651,393
| – | – | 3.51% | 7 |
|
|
2023
Q1 | $20.8M | Sell |
2,651,393
-545,053
| -17% | -$4.07M | 3.11% | 8 |
|
|
2022
Q4 | $21.6M | Buy |
3,196,446
+1,396,446
| +78% | +$7.48M | 3.14% | 10 |
|
|
2022
Q3 | $26.1M | Hold |
1,800,000
| – | – | 3.2% | 9 |
|
|
2022
Q2 | $17.7M | Buy |
1,800,000
+1,151,731
| +178% | +$12.7M | 2.69% | 11 |
|
|
2022
Q1 | $9.55M | Buy |
+648,269
| New | +$9.31M | 1.91% | 15 |
|
Other funds holding KALV
Tang Capital Management's KALV Position: Q2 2026 in Review
Tang Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 4,573,530 shares — an estimated $92.1M sold.
Tang Capital Management first reported a position in KALV in Q1 2022 and held it in 17 quarters. The position peaked at $92.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Tang Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Tang Capital Management sold 4,573,530 KalVista Pharmaceuticals shares in Q2 2026, an estimated $92.1M.
- Tang Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2022 and held it in 17 quarters.
- Tang Capital Management's KalVista Pharmaceuticals position peaked at $92.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.